

OPEXA THERAPEUTICS, INC.

FORM 8-K (Current report filing)

Filed 09/01/06 for the Period Ending 09/01/06

Address	2635 TECHNOLOGY FOREST BLVD. THE WOODLANDS, TX 77381
Telephone	(281) 272-9331
CIK	0001069308
Symbol	OPXA
SIC Code	2834 - Pharmaceutical Preparations
Industry	Biotechnology & Drugs
Sector	Healthcare
Fiscal Year	12/31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): September 1, 2006

Opexa Therapeutics, Inc.

(Exact Name of Registrant as Specified in Its Charter)

(Formerly PharmaFrontiers Corp.)

Texas

(State or Other Jurisdiction of Incorporation)

000-25513

(Commission File Number)

76-0333165

(I.R.S. Employer Identification No.)

2635 N. Crescent Ridge Drive
The Woodlands, Texas

(Address of Principal Executive Offices)

77381

(Zip Code)

Registrant's telephone number, including area code: (281) 272-9331

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events.

On September 1, 2006, Registrant announced that its common shares will be listed and begin trading on the NASDAQ Global Market. The Company's trading symbol, OPXA, will remain unchanged. Opexa's common shares will no longer be listed on the OTC Bulletin Board. A copy of the press release is attached as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits

(c) Exhibit 99.1

The following exhibit is to be filed as part of this 8-K:

Exhibit No. -----	Description -----
99.1	Press release issued September 1, 2006

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

OPEXA THERAPEUTICS, INC.

By: /s/ David B. McWilliams

David B. McWilliams, Chief Executive Officer

DATE: September 1, 2006

EXHIBIT INDEX

Exhibit No. -----	Description -----
99.1	Press release issued September 1, 2006

Opexa Shares to Trade on NASDAQ Global Market

THE WOODLANDS, Texas--(BUSINESS WIRE)--Sept. 1, 2006--Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company involved in the development and commercialization of cell therapies, today announced that its common shares will be listed and begin trading today on the NASDAQ Global Market. The Company's trading symbol, OPXA, will remain unchanged. Opexa's common shares will no longer be listed on the OTC Bulletin Board.

David B. McWilliams, chief executive officer of Opexa, commented, "We believe that this NASDAQ listing will afford us increased visibility within the investment community, while enhancing the trading liquidity of Opexa's shares. This is an important achievement and milestone for the Company, and is part of our ongoing efforts to maximize shareholder value."

About Opexa Therapeutics

Opexa Therapeutics develops and commercializes cell therapies to treat several major disease areas such as MS, rheumatoid arthritis, pancreatic and cardiac conditions. Opexa has exclusive license from Baylor College of Medicine for individualized cell therapies and has initiated a Phase IIb clinical trial to evaluate effectiveness in treating MS. The Company holds the exclusive worldwide license for an autologous T cell vaccine for rheumatoid arthritis from the Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences of the People's Republic of China. Opexa also holds the exclusive worldwide license from the University of Chicago, through its prime contractor relationship with Argonne National Laboratory, for patents relating to the use of adult pluripotent stem cells derived from patients' own circulating blood. For more information, visit the Opexa Therapeutics website at www.opexatherapeutics.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements about Opexa Therapeutics' growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. These forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Opexa Therapeutics' ability to obtain additional funding, develop its stem cell technologies, achieve its operational objectives, and obtain patent protection for its discoveries, that may cause Opexa Therapeutics' actual results to be materially different from any future results expressed or implied by such forward-looking statements. Opexa Therapeutics undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT: Opexa Therapeutics, Inc.
Lynne Hohlfeld, 281-719-3421 lhohlfeld@opexatherapeutics.com or
Investor Relations:

Lippert/Heilshorn & Associates

Kim Sutton Golodetz, 212-838-3777 kgolodetz@lhai.com
or
Bruce Voss, 310-691-7100
bvoss@lhai.com